Skip to main content
Premium Trial:

Request an Annual Quote

NGS Technology Firm Stratos Genomics Raises $10M

NEW YORK (GenomeWeb) – Stratos Genomics has raised $10 million toward a Series B financing round targeting $16.3 million.

The Seattle-based firm disclosed the raise in a Form D filed with the US Securities and Exchange Commission on Monday. In an email to GenomeWeb Daily News, Stratos Chairman and CEO Alan Stephan said the $10 million is the first close of a Series B round. He declined to comment further, saying more information will be released after the second close is completed.

In March, the firm told In Sequence that the Series B funding would go toward the development of a low-cost sequencing platform that combines the speed and throughput of nanopores with improved resolution and signal to noise, both for targeted and whole-genome sequencing.

Stratos was founded in 2007 as a spinout of engineering firm the Stratos Group. It raised $4 million in a Series A financing round in 2010 and garnered another $2.1 million in 2011 and $2 million in 2012 after it demonstrated that it was able to sequence a 36-base DNA template. Investors added a $2 million infusion last year after Stratos showed it could generate a 210-base read.

Stratos' technology, called sequencing by expansion, or SBX, converts DNA into a larger surrogate molecule containing reporter molecules that represent the DNA bases and generate a stronger signal, as company officials described to In Sequence. The surrogate molecule then passes through a nanopore with a detector to read out the signal, which is translated back into DNA sequence.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.